Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .

This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.

Trial Details

NCT ID

NCT07191249

Phase

PHASE2

Sponsor

Tel-Aviv Sourasky Medical Center

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Mosunetuzumab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, redirecting T cells to eliminate malignant B cells.

Locations (sample)

Haifa, Israel|32.81303,34.99928
Jerusalem, Israel|31.76904,35.21633
Jerusalem, Israel|31.76904,35.21633
Tel Aviv, Israel|32.08088,34.78057

Key Eligibility Criteria

at least 18 years old
Histologically confirmed classic FL (cFL) (according to WHO-HEAM4R classification)
Low tumor burden by GELF criteria
No prior therapy except surgery or radiotherapy for disease that was previously localized

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →